Dr. Tripathy on Ixabepilone in Patients With TNBC

Debu Tripathy, MD, chair, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the use of ixabepilone as a treatment for patients with triple-negative breast cancer (TNBC).

Ixabepilone is an epothilone agent that was approved by the FDA for its demonstrated efficacy in patients who are refractory to taxane-based therapies, Tripathy explains. The mechanism of action of ixabepilone differs from that of a taxane; patients who are resistant to taxanes will experience membrane transport.

However, questions do remain with optimal incorporation of ixabepilone. The clinical trials that led to the approval of ixabepilone compared capecitabine with or without ixabepilone. Findings showed that disease-free survival is improved with the combination, Tripathy says.

<<<

View more from the 33rd Annual Miami Breast Cancer Conference